Distribution and prognostic value of LymphGen genotyping in patients with diffuse large B-cell lymphoma.
10.3760/cma.j.issn.0253-2727.2022.04.007
- Author:
Fang ZHANG
1
;
Abulaiti RENAGULI
2
;
Xiao Long QI
2
;
Zhen KOU
2
;
Shun Sheng ZHAI
2
;
Wei TAN
2
;
Abuduer MUHEBAIER
2
;
Yu Ling NIE
2
;
Yan LI
2
Author Information
1. Medical School of Shihezi University, Shihezi 832001, China.
2. Department of Haematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
- Publication Type:Journal Article
- Keywords:
Distribution;
LymphGen genotyping;
Lymphoma, large B-cell, diffuse;
Next generation sequencing;
Prognosis
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Disease-Free Survival;
Genotype;
Humans;
Interleukin-1 Receptor-Like 1 Protein;
Lymphoma, Large B-Cell, Diffuse/drug therapy*;
Prognosis;
Retrospective Studies
- From:
Chinese Journal of Hematology
2022;43(4):305-310
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the distribution characteristics of LymphGen genotyping in a diffuse large B-cell lymphoma (DLBCL) population and verify its prognostic value. Methods: We collected the clinical data and paraffin-embedded tumor tissue samples of 155 patients with newly diagnosed DLBCL in the People's Hospital of Xinjiang Uygur Autonomous Region from June 2014 to December 2020. DNA was extracted from tumor tissue and 475 gene mutations were detected by next-generation sequencing technology. We investigated the distribution of LymphGen genotyping in the DLBCL population, patients with different COO genotypes in the Xinjiang region, and their effects on PFS and OS. Results: ①Among 155 patients, 105 patients (67.7%) could be genotyped, including 14 (9.0%) for MCD, 26 (16.8%) for BN2, 10 (6.5%) for N1, 8 (5.2%) for EZB, 27 (17.4%) for A53, and 20 (12.9%) for ST2. ②The distribution of each gene subtype was different in different cell origin (COO) types (P=0.021) . ST2 was dominant in the germinal center type (GCB) group (28.8%) , and A53 and MCD were dominant in the non-GCB group (35.8%, 17.0%) . The BN2 type was the most common in both groups (23.1%, 26.4%) . ③There were statistically significant differences in progression-free survival (PFS) and overall survival (OS) among different gene subtypes (P=0.031 and 0.005, respectively) . N1 and A53 had poor prognosis. The 2-year PFS and OS rates of N1 were both (21.3±18.4) %, and the 3-year PFS and OS rates of A53 were (60.9±11.3) %, (46.8±10.9) %, respectively. ④ The 3-year PFS and OS rates of MCD were the best, but the 5-year PFS and OS rates were worse. ⑤In the ROC curve of LymphGen genotyping for OS prediction, the AUC was 0.66, showing a certain degree of differentiation. Conclusion: LymphGen genotyping in the DLBCL population was different from previous reports and was of great significance for the prognosis of patients with DLBCL.
